Table of Contents
Executive Summary
- Overview
- Key disease markets
- Key drug classes
- Key products
- Key companies
- Key trends and opportunities
Chapter 1. Overview of Global CNS Market
- Global CNS market
- Report overview
Chapter 2. Key CNS Disease Markets
- Key CNS markets
- Disease burden
- CNS prevalence
- CNS mortality
- CNS epidemiology
- ADHD (Attention Deficit Hyperactivity Disorder)
- Alzheimer' s disease
- Depression
- Epilepsy
- Migraine
- Parkinson' s disease
- Schizophrenia
Chapter 3. Key CNS Drug Classes
- Key drug classifications
- Anti-depressants drug class
- Leading anti-depressant drugs
- Anti-psychotics drug class
- Epilepsy drug class
- Alzheimer' s disease drug class
- Leading Alzheimer' s disease drugs
- Migraine drug class
- ADHD drug class
- Parkinson' s disease drug class
- Leading Parkinson' s disease drugs
- Selected other drug classes
- Leading selected other CNS drugs
Chapter 4. Key CNS Products
- Leading products
- Top 10 leading CNS drugs
- Zyprexa (olanzapine)
- Risperdal (risperidone)
- Effexor (venlafaxine)
- Zoloft (sertraline)
- Seroquel (quetiapine)
- Lexapro/ Cipralex (escitalopram)
- Aricept (donepezil)
- Topamax (topiramate)
- Lamictal (lamotrigine)
- Wellbutrin (bupropion)
Chapter 5. Key Companies Involved in CNS
- Major CNS players
- Leading companies
- Johnson & Johnson
- Pfizer
- Eli Lilly
- GlaxoSmithKline
- AstraZeneca
- Wyeth
- Novartis
- Forest
- Abbott
- Sanofi-Aventis
Chapter 6. Key Trends and Opportunities in CNS
- Key disease market forecasts
- Key drug class forecasts
- Anti-depressants
- Anti-psychotics
- Epilepsy
- Alzheimer' s disease
- Migraine
- ADHD
- Parkinson' s disease
- Selected others
- Key product forecasts
- Zyprexa (olanzapine)
- Risperdal (risperidone)
- Effexor (venlafaxine)
- Zoloft (sertraline)
- Seroquel (quetiapine)
- Lexapro/ Cipralex (escitalopram)
- Aricept (donepezil)
- Topamax (topiramate)
- Lamictal (lamotrigine)
- Wellbutrin (bupropion)
- Forecast patent expiries
- Company forecasts in the CNS area
- Johnson & Johnson
- Pfizer
- Eli Lilly
- GlaxoSmithKline
- AstraZeneca
- Wyeth
- Novartis
- Forest
- Abbott
- Sanofi-Aventis
Appendix
- Proprietary data sources
- Product Trends Database
- R&D Trends Database
- Company Trends Database
- Top 48 CNS products
- Top 15 pharmaceutical companies by CNS sales
Figures
- Figure 1: Global CNS market, 2003-2005
- Figure 2: Report structure
- Figure 3: Disease burden for CNS in seven major pharmaceutical markets,
2005
- Figure 4: Prevalence for CNS in seven major pharmaceutical markets, 2005
- Figure 5: CNS deaths in seven major pharmaceutical markets, 2005
- Figure 6: CNS epidemiology in seven major markets, 2005
- Figure 7: ADHD epidemiology in seven major markets, 2005
- Figure 8: Alzheimer' s disease epidemiology in seven major markets, 2005
- Figure 9: Depression epidemiology in seven major markets, 2005
- Figure 10: Epilepsy epidemiology in seven major markets, 2005
- Figure 11: Migraine epidemiology in seven major markets, 2005
- Figure 12: Parkinson' s disease epidemiology in seven major markets, 2005
- Figure 13: Schizophrenia epidemiology in seven major markets, 2005
- Figure 14: Global CNS market by drug class, 2005
- Figure 15: Global CNS market by drug class, 2003-2005
- Figure 16: Global CNS market trends by drug class, 2004-2005
- Figure 17: Anti-depressants drugs market, 2003-2005
- Figure 18: Leading anti-depressant drugs by approval date, 1980-2005
- Figure 19: Anti-psychotics drugs market, 2003-2005
- Figure 20: Leading anti-psychotics by approval date, 1989-2005
- Figure 21: Epilepsy drugs market, 2003-2005
- Figure 22: Leading epilepsy drugs by approval date, 1968-2005
- Figure 23: Alzheimer' s disease drugs market, 2003-2005
- Figure 24: Leading Alzheimer' s disease drugs by approval date, 1996-2005
- Figure 25: Migraine drugs market, 2003-2005
- Figure 26: Leading migraine drugs by approval date, 1992-2005
- Figure 27: ADHD drugs market, 2003-2005
- Figure 28: Leading ADHD drugs by approval date, 1996-2005
- Figure 29: Parkinson' s disease market, 2003-2005
- Figure 30: Leading Parkinson' s disease drugs by approval date, 1997-2005
- Figure 31: Selected others market, 2003-2005
- Figure 32: Leading selected other CNS drugs by approval date, 1968-2005
- Figure 33: Top 10 CNS products by global sales, 2005
- Figure 34: Top 10 companies by global CNS sales, 2005
- Figure 35: Top 10 companies by global CNS market share, 2005
- Figure 36: Top 10 companies by global CNS sales, 2004-2005
- Figure 37: CNS incidence forecasts by geographic market, 2005-2010
- Figure 38: CNS incidence forecasts by disease market, 2005-2010
- Figure 39: Global CNS market forecast, 2003-2010
- Figure 40: Global CNS market forecasts by drug class, 2003-2010
- Figure 41: Top 10 CNS drugs by forecast sales, 2010
- Figure 42: Zyprexa (olanzapine) forecast sales, 2003-2010
- Figure 43: Risperdal (risperidone) forecast sales, 2003-2010
- Figure 44: Effexor (venlafaxine) forecast sales, 2003-2010
- Figure 45: Zoloft (sertraline) forecast sales, 2003-2010
- Figure 46: Seroquel (quetiapine) forecast sales, 2003-2010
- Figure 47: Lexapro/ Cipralex (escitalopram) forecast sales, 2003-2010
- Figure 48: Aricept (donepezil) forecast sales, 2003-2010
- Figure 49: Topamax (topiramate) forecast sales, 2003-2010
- Figure 50: Lamictal (lamotrigine) forecast sales, 2003-2010
- Figure 51: Wellbutrin (bupropion) forecast sales, 2003-2010
- Figure 52: Forecast patent expiries by 2005 global sales, 2006-2015
- Figure 53: Top ten companies by CNS sales trends, 2005-2010
Tables
- Table 1: Global CNS market trends by drug class, 2003-2005
- Table 2: Leading anti-depressant drugs, 2005
- Table 3: Anti-depressants market trends, 2003-2005
- Table 4: Leading anti-psychotics, 2005
- Table 5: Anti-psychotics market trends, 2003-2005
- Table 6: Leading epilepsy drugs, 2005
- Table 7: Epilepsy drug market trends, 2003-2005
- Table 8: Leading Alzheimer' s disease drugs, 2005
- Table 9: Alzheimer' s disease drug market trends, 2003-2005
- Table 10: Leading migraine drugs, 2005
- Table 11: Migraine drugs market trends, 2003-2005
- Table 12: Leading ADHD drugs, 2005
- Table 13: ADHD drugs market trends, 2003-2005
- Table 14: Leading Parkinson' s disease drugs, 2005
- Table 15: Parkinson' s disease market trends, 2003-2005
- Table 16: Leading selected other CNS drugs, 2005
- Table 17: selected others market trends, 2003-2005
- Table 18: Top 20 CNS products by global sales, 2003-2005
- Table 19: Zyprexa (olanzapine) profile, 2005
- Table 20: Risperdal (risperidone) profile, 2005
- Table 21: Effexor (venlafaxine) profile, 2005
- Table 22: Zoloft (sertraline) profile, 2005
- Table 23: Seroquel (quetiapine) profile, 2005
- Table 24: Lexapro (escitalopram) profile, 2005
- Table 25: Aricept (donepezil) profile, 2005
- Table 26: Topamax (topiramate) profile, 2005
- Table 27: Lamictal (lamotrigine) profile, 2005
- Table 28: Wellbutrin (bupropion) profile, 2005
- Table 29: Top 10 companies by global CNS sales, 2003-2005
- Table 30: Johnson & Johnson profile, 2005
- Table 31: Johnson & Johnson pipeline, 2005
- Table 32: Pfizer profile, 2005
- Table 33: Pfizer CNS pipeline, 2005
- Table 34: Eli Lilly profile, 2005
- Table 35: Eli Lilly CNS pipeline, 2005
- Table 36: GlaxoSmithKline profile, 2005
- Table 37: GlaxoSmithKline CNS pipeline, 2005
- Table 38: AstraZeneca profile, 2005
- Table 39: AstraZeneca CNS pipeline, 2005
- Table 40: Wyeth profile, 2005
- Table 41: Wyeth CNS pipeline, 2005
- Table 42: Novartis profile, 2005
- Table 43: Novartis CNS pipeline, 2005
- Table 44: Forest profile, 2005
- Table 45: Forest CNS pipeline, 2005
- Table 46: Abbott profile, 2005
- Table 47: Abbott CNS pipeline, 2005
- Table 48: Sanofi-Aventis profile, 2005
- Table 49: Sanofi-Aventis CNS pipeline, 2005
- Table 50: Global CNS market forecasts by drug class, 2003-2010
- Table 51: Top 10 CNS drugs forecasts, 2003-2010
- Table 52: Top 10 companies by CNS sales forecasts, 2005-2010
- Table 53: Top 48 CNS products by global pharmaceutical sales, 2003-2005
- Table 54: Top 15 companies by global CNS sales, 2003-2005
|
Related Report
|
View Cart
